New dynamic duo targets Hard-to-Treat liver cancer

NCT ID NCT06726161

Recruiting now Disease control Sponsor: RayzeBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two new drugs: one to help spot liver cancer cells (RYZ811) and another to deliver treatment directly to them (RYZ801). It is for people with a type of liver cancer called GPC3-positive hepatocellular carcinoma that cannot be removed by surgery. The goal is to see if the treatment shrinks tumors better than current standard therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Research Facility
RECRUITING

Birmingham, Alabama, 35233, United States
Research Facility
RECRUITING

Phoenix, Arizona, 85054, United States
Research Facility
RECRUITING

Tucson, Arizona, 85719, United States
Research Facility
RECRUITING

Orange, California, 92868, United States
Research Facility
RECRUITING

Jacksonville, Florida, 32224, United States
Research Facility
RECRUITING

Lexington, Kentucky, 40536, United States
Research Facility
RECRUITING

Baltimore, Maryland, 21287, United States
Research Facility
RECRUITING

Rochester, Minnesota, 55905, United States
Research Facility
RECRUITING

Omaha, Nebraska, 68130, United States
Research Facility
RECRUITING

New York, New York, 10065, United States
Research Facility
RECRUITING

Houston, Texas, 77030, United States
Research Facility
RECRUITING

Charlottesville, Virginia, 22908, United States
Research Facility
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.